Subscribe
shutterstock_1349461175_pavel_kapysh-3
Pavel Kapysh / Shutterstock.com
18 November 2020Americas

Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen

Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
PTAB grants review of Seagen patent on eve of court’s infringement ruling
11 April 2022   The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu breast cancer treatment.
Americas
Pyxis secures ADC licence from Pfizer
22 March 2021   Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.
Americas
AstraZeneca to buy Alexion for $39bn
14 December 2020   AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Big Pharma
PTAB grants review of Seagen patent on eve of court’s infringement ruling
11 April 2022   The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu breast cancer treatment.
Americas
Pyxis secures ADC licence from Pfizer
22 March 2021   Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.
Americas
AstraZeneca to buy Alexion for $39bn
14 December 2020   AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

More on this story

Big Pharma
PTAB grants review of Seagen patent on eve of court’s infringement ruling
11 April 2022   The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu breast cancer treatment.
Americas
Pyxis secures ADC licence from Pfizer
22 March 2021   Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.
Americas
AstraZeneca to buy Alexion for $39bn
14 December 2020   AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?